Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194783 | 1.00 | MAOB (0.43) | MAOBGPR183PTGES2ALDH1A1AHR | |
| SCHEMBL3668286 | 1.00 | MAOB (0.43) | MAOBGPR183PTGES2ALDH1A1AHR | |
| SCHEMBL7736953 | 1.00 | MAOB (0.43) | MAOBGPR183PTGES2ALDH1A1AHR | |
| SCHEMBL15673888 | 0.92 | TNFRSF1A (0.42) | TNFRSF1APTGS2HSD11B1NFE2L2 | |
| SCHEMBL6911087 | 0.92 | AHR (0.44) | MAOBAHRPTGS2CYP1A2NFE2L2 | |
| SCHEMBL1194120 | 0.92 | AHR (0.44) | MAOBAHRPTGS2CYP1A2NFE2L2 | |
| SCHEMBL1195539 | 0.85 | PTGS2 (0.41) | MAOBAHRPTGS2CYP1A2NFE2L2 | |
| SCHEMBL1194057 | 0.84 | MAOB (0.50) | MAOBALDH1A1AHRMAPTPTGS2 | |
| SCHEMBL1194100 | 0.84 | MAPT (0.40) | GPR183PTGES2ALDH1A1NPC1MAPT | |
| SCHEMBL5872258 | 0.84 | TNFRSF1A (0.37) | GPR183TNFRSF1APTGS2HSD11B1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4780885-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | claimed |
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090247624-A1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA BETA UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS INC. (US) | 2009-10-01 | — | — | US | claimed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | claimed |
| EP-2046343-A2 | FORMULATIONS OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | Onconova Therapeutics, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| EP-1370253-B8 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2008105808-A2 | FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES | ONCONOVA THERAPEUTICS, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| EP-1370253-B1 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1909775-A2 | FORMULATION OF RADIOPROTECTIVE ALPHA, BETA UNSATURATED ARYL SULFONES | Onconova Therapeutics, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| US-6667346-B2 | Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-23 | — | — | US | claimed |
| EP-1370253-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH $g(a), $g(b) UNSATURATED ARYL SULFONES | Temple University of the Commonwealth System of Higher Education (US) | 2003-12-17 | — | — | EP | claimed |
| US-6548553-B2 | Therapy of proliferative disease other than prostate or breast cancer comprising administering styryl sulfone derivative | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-04-15 | — | — | US | claimed |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ONCONOVA THERAPEUTICS, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2002069892-A2 | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-12 | — | — | WO | claimed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | claimed |
| US-6414034-B1 | ANTICANCER AGENTS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-07-02 | — | — | US | claimed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | claimed |
| US-20020022666-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-02-21 | — | — | US | claimed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247624-A1 | FORMULATIONS OF RADIOPROTECTIVE ALPHA BETA UNSATURATED ARYL SULFONES | ARSA, DEGS1, AHR | MAOB 1660/4885GPR183 1073/4885PTGES2 427/4885 |
| US-20030060505-A1 | Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones | ARSA, SULT2A1, CYP2S1 | MAOB 2545/4885GPR183 2226/4885PTGES2 626/4885 |
| US-20020022666-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | MAOB 3488/4885GPR183 2303/4885PTGES2 4127/4885 |
| US-20110028504-A1 | Formulation of radioprotective alpha beta unsaturated aryl sulfones | DEGS1, ARSA, ABCE1 | MAOB 1985/4885GPR183 1775/4885PTGES2 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.